Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in Adults

This randomized, double-blind, noninferiority trial was designed to demonstrate that pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 mg) was at least as effective clinically as amoxicillin-clavulanate 875/125 mg, both given twice daily for 7 days, in the treatment of community-acquir...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: File, T. M., Lode, H., Kurz, H., Kozak, R., Xie, H., Berkowitz, E.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology (ASM) 2004
Teme:
Clinical Therapeutics
Online pristup:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC514768/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15328092/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.9.3323-3331.2004
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items